Costs of fluoroquinolone resistance in clinical E. coli: a potential explanation for similarities in resistance between the UK and Canada

BBSRC：罗西·克洛弗：BB/M011208/1一些细菌中和抗生素的影响(抗生素耐药性)的能力已经成为一个广泛的全球健康问题。在缺乏抗生素的情况下，了解抗生素耐药性对细菌生长的影响是至关重要的。之前的研究表明，在没有抗生素的情况下，耐药性会减少细菌的生长，这导致了一个被广泛接受的概念，即减少抗生素治疗将减少耐药细菌的出现和传播。然而，这项研究的大部分都是在实验室生物体上进行的。为了了解减少抗生素治疗是否是一种有效的策略，需要在临床组织中考虑这些机制。为了解决目前研究中的差距，我们将研究临床大肠杆菌对一种常用抗生素(氟喹诺酮类)的耐药性的影响。加拿大和英国对氟喹诺酮类药物的使用有所不同。加拿大倾向于使用氟喹诺酮作为尿路感染的常见治疗方法，而英国优先选择其他抗生素类别。然而，氟喹诺酮类药物的耐药率是相似的，这使得人们不清楚开出的氟喹诺酮类药物是否会影响耐药率。在常见的实验室生物体中，对氟喹诺酮类药物的耐药性与细菌生长严重减少有关。然而，实验室生物和临床生物之间耐药对生长的影响的差异可能解释了为什么临床生物的耐药率相似，尽管处方的比率不同。如果在缺乏抗生素的情况下，对氟喹诺酮类药物的耐药性不会减少临床细菌的生长，这可能有助于解释为什么加拿大和英国的耐药率相似，尽管它们的处方做法不同。

BBSRC : Rosie Clover : BB/M011208/1 The ability of some bacteria to counteract the effects of antibiotics (antibiotic resistance) has become an extensive global health issue. Understanding the effects of antibiotic resistance on bacterial growth in the absence of antibiotics is vital. Previous research has suggested that resistance reduces bacterial growth in the absence of antibiotics, leading to the widely accepted concept that suggest a reduction in antibiotic therapies will reduce the emergence and spread of resistant bacteria. However, the majority of this research has been conducted on laboratory organisms. To understand whether reducing antibiotic therapies is an effective strategy, these mechanisms need to be considered in clinical organisms.To address the current gap in research, we will study the effects of resistance to a commonly-prescribed class of antibiotics (fluoroquinolones) in clinical Escherichia coli. Use of fluoroquinolones differs between Canada and the UK. Canada tends to use fluoroquinolone as a common treatment for urinary tract infections, whereas the UK preferentially opts for other antibiotic classes. Yet the rates of fluoroquinolone resistance are similar, making it unclear whether the fluoroquinolone prescribing influences the rate of resistance. In common laboratory organisms, fluoroquinolone resistance is associated with extensively reduced bacterial growth. However, differences in the effects of resistance on growth between laboratory organisms and clinical organisms may explain why resistance rates in clinical organisms are similar despite different rates of prescription. If fluoroquinolone resistance does not reduce the growth of clinical organisms in the absence of antibiotics, this could help to explain why rates of resistance in Canada and the UK are similar despite their different prescribing practises.